Skip to main content

Advertisement

Figure 7 | Molecular Brain

Figure 7

From: Pharmacological enhancement of mGlu1 metabotropic glutamate receptors causes a prolonged symptomatic benefit in a mouse model of spinocerebellar ataxia type 1

Figure 7

Ro0711401 treatment does not change the distribution profile of vGluT2 immunostaining in the cerebellum of wild-type and symptomatic SCA1 mice. Wild-type and SCA1 mice (n = 3 per group) received a single s.c. injection of vehicle or Ro0711401 (10 mg/kg), and were killed after 6 days. Representative sections from 2 individual mice per group are shown. Note the increased vGluT2 immunostaining in the cerebellar granular layer of SCA1 mice.

Back to article page